Autor:  PD Dr. med. Barbara Ludwig - Datum: 22.11.2017

Allogene Inseltransplantation bei Diabetes mellitus Typ 1 - Herausforderungen und Perspektiven

Trotz großer Fortschritte im Bereich der Inseltransplantation stehen einige Faktoren einer breiteren Anwendung dieser Therapieoption entgegen. Aufgrund der aktuellen Limitationen werden derzeit werden verschiedene therapeutische Strategien entwickelt, um das klinische Outcome der Inseltransplantation zu verbessern.

PD Dr. Barbara Ludwig erläutert im Folgenden die aktuellen Herausforderungen und mögliche therapeutische Perspektiven:

Literatur

  1. Vivot K, Langlois A, Jeandidier N, et al. Instant blood-mediated inflammatory reaction during islet transplantation: the role of Toll-like receptors signaling pathways. Transplant Proc 2011; 43: 3192-3194
  2. Bernard-Kargar C, Ktorza A. Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 2001; 50 Suppl 1: S30-35
  3. Bouwens L. Beta cell regeneration. Current diabetes reviews 2006; 2: 3-9
  4. Dhawan S, Georgia S, Bhushan A. Formation and regeneration of the endocrine pancreas. Current opinion in cell biology 2007; 19: 634-645
  5. Hanley SC, Austin E, Assouline-Thomas B, et al. {beta}-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 2010; 151: 1462-1472
  6. Hill DJ. Nutritional programming of pancreatic beta-cell plasticity. World journal of diabetes 2011; 2: 119-126
  7. Ilegems E, Dicker A, Speier S, et al. Reporter islets in the eye reveal the plasticity of the endocrine pancreas. Proc Natl Acad Sci U S A 2013; 110: 20581-20586
  8. Juhl K, Bonner-Weir S, Sharma A. Regenerating pancreatic beta-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis. Curr Opin Organ Transplant 2010; 15: 79-85
  9. Karaca M, Magnan C, Kargar C. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Diabetes Metab 2009; 35: 77-84
  10. Khalaileh A, Gonen-Gross T, Magenheim J, et al. Determinants of pancreatic beta-cell regeneration. Diabetes, obesity & metabolism 2008; 10 Suppl 4: 128-135
  11. Mezza T, Kulkarni RN. The regulation of pre- and post-maturational plasticity of mammalian islet cell mass. Diabetologia 2014; 57: 1291-1303
  12. Ninov N, Hesselson D, Gut P, et al. Metabolic regulation of cellular plasticity in the pancreas. Current biology : CB 2013; 23: 1242-1250
  13. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. The Journal of clinical investigation 2007; 117: 2553-2561
  14. Palau N, Rebuffat SA, Altirriba J, et al. Role of IGFBP-3 in the regulation of beta-cell mass during obesity: adipose tissue/beta-cell cross talk. Endocrinology 2012; 153: 177-187
  15. Thorel F, Nepote V, Avril I, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010; 464: 1149-1154
  16. Tschen SI, Dhawan S, Gurlo T, et al. Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 2009; 58: 1312-1320
  17. Brennand K, Melton D. Slow and steady is the key to beta-cell replication. Journal of cellular and molecular medicine 2009; 13: 472-487
  18. Aaboe K, Krarup T, Madsbad S, et al. GLP-1: physiological effects and potential therapeutic applications. Diabetes, obesity & metabolism 2008; 10: 994-1003
  19. Bosi E. Time for testing incretin therapies in early type 1 diabetes? The Journal of clinical endocrinology and metabolism 2010; 95: 2607-2609
  20. Issa CM, Azar ST. Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Curr Diab Rep 2012; 12: 560-567
  21. Ludwig B, Barthel A, Reichel A, et al. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus. Vitamins and hormones 2014; 95: 195-222
  22. Perez-Arana G, Blandino-Rosano M, Prada-Oliveira A, et al. Decrease in {beta}-cell proliferation precedes apoptosis during diabetes development in bio-breeding/worcester rat: beneficial role of Exendin-4. Endocrinology 2010; 151: 2538-2546
  23. Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Experimental diabetes research 2011; 2011: 376509
  24. Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 2008; 57: 3281-3288
  25. Achenbach P, Bonifacio E, Koczwara K, et al. Natural history of type 1 diabetes. Diabetes 2005; 54 Suppl 2: S25-31
  26. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346
  27. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769
  28. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608
  29. Bonifacio E, Achenbach P, Pan L, et al. Mucosal insulin vaccination for type 1 diabetes prevention. Exp Clin Endocrinol Diabetes 2008; 116 Suppl 1: S26-29
  30. Huppmann M, Baumgarten A, Ziegler AG, et al. Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care 2005; 28: 1204-1206
  31. Ross LF, Philipson LH. Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus. JAMA : the journal of the American Medical Association 2007; 298: 285; author reply 285-286
  32. Skyler JS. Cellular therapy for type 1 diabetes: has the time come? JAMA : the journal of the American Medical Association 2007; 297: 1599-1600
  33. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA : the journal of the American Medical Association 2007; 297: 1568-1576
  34. 2007 update on allogeneic islet transplantation from the Collaborative Islet Transplant Registry (CITR). Cell Transplant 2009; 18: 753-767
  35. Lehmann R, Pavlicek V, Spinas GA, et al. [Islet transplantation in type I diabetes mellitus]. Therapeutische Umschau Revue therapeutique 2005; 62: 481-486
  36. Lehmann R, Spinas GA, Moritz W, et al. Has time come for new goals in human islet transplantation? Am J Transplant 2008; 8: 1096-1100
  37. Ludwig B, Ludwig S, Steffen A, et al. Islet versus pancreas transplantation in type 1 diabetes: competitive or complementary? Curr Diab Rep 2010; 10: 506-511
  38. Berney T, Johnson PR. Donor pancreata: evolving approaches to organ allocation for whole pancreas versus islet transplantation. Transplantation 2010; 90: 238-243
  39. Brooks AM, Walker N, Aldibbiat A, et al. Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations. Am J Transplant 2013; 13: 3236-3243
  40. Johnson PR, Jones KE. Pancreatic islet transplantation. Seminars in pediatric surgery 2012; 21: 272-280
  41. Mittal S, Johnson P, Friend P. Pancreas transplantation: solid organ and islet. Cold Spring Harb Perspect Med 2014; 4: a015610
  42. Korsgren O, Nilsson B, Berne C, et al. Current status of clinical islet transplantation. Transplantation 2005; 79: 1289-1293
  43. Kempf MC, Andres A, Morel P, et al. Logistics and transplant coordination activity in the GRAGIL Swiss-French multicenter network of islet transplantation. Transplantation 2005; 79: 1200-1205
  44. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 1576; 12: 1576-1583
  45. Goto M, Johansson U, Eich TM, et al. Key factors for human islet isolation and clinical transplantation. Transplant Proc 2005; 37: 1315-1316
  46. Lakey JR, Burridge PW, Shapiro AM. Technical aspects of islet preparation and transplantation. Transpl Int 2003; 16: 613-632
  47. Stegall MD, Dean PG, Sung R, et al. The rationale for the new deceased donor pancreas allocation schema. Transplantation 2007; 83: 1156-1161
  48. Armann B, Hanson MS, Hatch E, et al. Quantification of basal and stimulated ROS levels as predictors of islet potency and function. Am J Transplant 2007; 7: 38-47
  49. Hanson MS, Park EE, Sears ML, et al. A Simplified Approach to Human Islet Quality Assessment. Transplantation 2010; 89: 1178-1188
  50. Kaddis J, Danobeitia J, Niland J, et al. Multi-Center Analysis of Novel and Established Variables Associated with Successful Human Islet Isolation Outcomes. Am J Transplant 2010; 10: 646-656
  51. Ren J, Jin P, Wang E, et al. Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation. Journal of Translational Medicine 2007; 5: 1
  52. Qi M, Barbaro B, Wang S, et al. Human pancreatic islet isolation: Part I: digestion and collection of pancreatic tissue. Journal of visualized experiments : JoVE 2009, DOI: 10.3791/1125
  53. Qi M, Barbaro B, Wang S, et al. Human pancreatic islet isolation: Part II: purification and culture of human islets. Journal of visualized experiments : JoVE 2009, DOI: 10.3791/1343
  54. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep 2011; 11: 345-354
  55. Cardani R, Pileggi A, Ricordi C, et al. Allosensitization of islet allograft recipients. Transplantation 2007; 84: 1413-1427
  56. McCall M, James Shapiro AM. Update on islet transplantation. Cold Spring Harb Perspect Med; 2: a007823
  57. Reffet S, Thivolet C. Immunology of pancreatic islet transplantation. Diabetes Metab 2006; 32: 523-526
  58. Buss JL, Rajab A, Essig ED, et al. Exenatide Pretreatment Improved Graft Function in Nonhuman Primate Islet Recipients Compared to Treatment after Transplant Only. J Transplant 2012; 2012
  59. Jung DY, Park JB, Joo SY, et al. Effect of nicotinamide on early graft failure following intraportal islet transplantation. Experimental & Molecular Medicine 2009; 41: 782-792
  60. Chhabra P, Brayman KL. Current Status of Immunomodulatory and Cellular Therapies in Preclinical and Clinical Islet Transplantation. J Transplant 2011; 2011
  61. Citro A, Cantarelli E, Maffi P, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. The Journal of clinical investigation 2012; 122: 3647-3651
  62. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. The Journal of clinical investigation 2008; 118: 1806-1814
  63. Monti P, Scirpoli M, Maffi P, et al. Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells. Diabetes 2008; 57: 2341-2347
  64. Cantarelli E, Piemonti L. Alternative transplantation sites for pancreatic islet grafts. Curr Diab Rep 2011; 11: 364-374
  65. Merani S, Toso C, Emamaullee J, et al. Optimal implantation site for pancreatic islet transplantation. The British journal of surgery 2008; 95: 1449-1461
  66. Rajab A. Islet transplantation: alternative sites. Curr Diab Rep 2010; 10: 332-337
  67. Schubert U, Schmid J, Lehmann S, et al. Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone. Proc Natl Acad Sci U S A 2013; 110: 2288-2293
  68. Aigner B, Klymiuk N, Wolf E. Transgenic pigs for xenotransplantation: selection of promoter sequences for reliable transgene expression. Curr Opin Organ Transplant 2010; 15: 201-206
  69. Buder B, Alexander M, Krishnan R, et al. Encapsulated Islet Transplantation: Strategies and Clinical Trials. Immune network 2013; 13: 235-239
  70. McCall MD, Toso C, Baetge EE, et al. Are stem cells a cure for diabetes? Clinical science (London, England : 1979) 2010; 118: 87-97
  71. Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nature biotechnology 2008; 26: 443-452
  72. Schulz TC, Young HY, Agulnick AD, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One 2012; 7: e37004
  73. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676
  74. Zhang D, Jiang W, Liu M, et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell research 2009; 19: 429-438
  75. Borowiak M, Melton DA. How to make beta cells? Current opinion in cell biology 2009; 21: 727-732
  76. Dufrane D, Goebbels RM, Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation 2010; 90: 1054-1062
  77. Dufrane D, Goebbels RM, Saliez A, et al. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation 2006; 81: 1345-1353
  78. Elliott RB. Towards xenotransplantation of pig islets in the clinic. Curr Opin Organ Transplant 2010; 16: 195-200
  79. Elliott RB, Escobar L, Calafiore R, et al. Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys. Transplant Proc 2005; 37: 466-469
  80. Elliott RB, Escobar L, Tan PL, et al. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 2007; 14: 157-161
  81. Reichart B, Niemann H, Chavakis T, et al. Xenotransplantation of porcine islet cells as a potential option for the treatment of type 1 diabetes in the future. Horm Metab Res 2015; 47: 31-35
  82. Groth CG, Korsgren, O., Tibell, A., Tollemar, J., Möller, E., Bolinder, J., Ostman, J., Reinholt, F.P., Hellerström, C., and Andersson, A. . Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994; 344: 1402-1404
  83. Valdes-Gonzalez R, Rodriguez-Ventura AL, White DJG, et al. Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets. Clinical and Experimental Immunology 2010; 162: 537-542
  84. Potter KJ, Abedini A, Marek P, et al. Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts. Proc Natl Acad Sci U S A 2010; 107: 4305-4310
  85. Westwell-Roper C, Dai DL, Soukhatcheva G, et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011; 187: 2755-2765
  86. Ludwig B, Ludwig S. Transplantable bioartificial pancreas devices: current status and future prospects. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 2015; 400: 531-540
  87. Barkai U, Weir GC, Colton CK, et al. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant 2013; 22: 1463-1476
  88. Ludwig B, Rotem A, Schmid J, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A 2012; 109: 5022-5027
  89. Ludwig B, Zimerman B, Steffen A, et al. A novel device for islet transplantation providing immune protection and oxygen supply. Horm Metab Res 2010; 42: 918-922
  90. Neufeld T, Ludwig B, Barkai U, et al. The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS One 2013; 8: e70150
  91. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci U S A 2013; 110: 19054-19058

Autor: PD Dr. med. Barbara Ludwig

PD Dr. med. Barbara Ludwig
Universitätsklinikum Carl Gustav Carus
Medizinische Klinik und Poliklinik III und Zentrum für Regenerative Therapien Dresden
Technische Universität Dresden
und
Paul Langerhans Institut Dresden des Helmholtz Zentrum München am Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
Medizinische Fakultät
DZD - Deutsches Zentrum für Diabetesforschung

Disclosures

Es besteht kein Interessenskonflikt.

Kommentare (0)

Keine Kommentare gefunden!

Neuen Kommentar schreiben